LB Pharmaceuticals targets $321.6m IPO

The IPO window seems to be reopening this autumn and companies seeking liquidity are re-entering the market, as in the case of LB Pharmaceuticals, which needs new capital to pursue its research. The biotech company, which is aiming for a listing on the Nasdaq, announced yesterday an overall valuation target of $321.6 million, partly because it can already count on underwriters for the offer such as Leerink Partners, Piper Sandler and Stifel.

The deal is expected to allow LB Pharmaceuticals to raise up to USD 266.7 million against the sale of 16.7 million shares at a price of between USD 14 and 16. The proceeds of the offering will then be used to advance the clinical development of its lead drug LB-102 for acute schizophrenia and bipolar depression. If an average value in the identified price range of $15 is taken into account, the biopharmaceutical company could raise around $228.5 million, which could rise to $263.4 million if the underwriters exercise the option to buy an additional 2.5 million shares.

As of 30 June, LB Pharmaceuticals had only $14.2 million in cash on hand. A sign that much of what was raised from venture capital has already been invested, as the company had received more than $120 million from investors including Deep Track Capital, Pontifax, TCG Crossover Fund, and Vida Ventures. However, the New York-based biotech wanted to reassure the market by stating that the proceeds of the IPO, together with the company's resources, will be sufficient to fund operating expenses and capital expenditure needs until the first quarter of 2028.

Founded in 2015, the company develops therapies in the neurological and neuropsychiatric fields. The main drug under study is LB-102, an oral medicine in late-stage research for the treatment of acute schizophrenia, which involves a sudden and intense onset of psychotic symptoms. The next steps in the research are to start a six-week late-phase study of LB-102 in patients with acute schizophrenia in the first quarter of 2026.